GNF-7 is primarily utilized in biomedical research due to its role as a selective inhibitor of Bcr-Abl tyrosine kinase, including its T315I mutant form. This makes it a valuable tool in studying chronic myeloid leukemia (CML) and understanding drug resistance mechanisms. Researchers employ GNF-7 to investigate potential therapeutic strategies for CML, particularly in cases where resistance to standard treatments like imatinib occurs. Additionally, its inhibitory effects on other kinases contribute to its use in broader cancer research, helping to explore signaling pathways and develop targeted therapies. Its application extends to preclinical studies, where it aids in evaluating efficacy and safety profiles of novel drug candidates.